{"id":2245,"date":"2026-06-04T03:50:11","date_gmt":"2026-06-04T03:50:11","guid":{"rendered":"https:\/\/www.pharglass.com\/?p=2245"},"modified":"2026-06-04T05:57:12","modified_gmt":"2026-06-04T05:57:12","slug":"mid-borosilicate-vs-low-borosilicate-glass-vials-for-pharmaceutical-packaging-composition-key-differences-pros-and-cons","status":"publish","type":"post","link":"https:\/\/www.pharglass.com\/de\/mid-borosilicate-vs-low-borosilicate-glass-vials-for-pharmaceutical-packaging-composition-key-differences-pros-and-cons\/","title":{"rendered":"Mid\u2011Borosilicate vs. Low\u2011Borosilicate Glass Vials for Pharmaceutical Packaging: Composition, Key Differences, Pros, and Cons"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Introduction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical glass vials are the backbone of parenteral drug containment. Their material composition directly affects drug stability, container closure integrity, and patient safety. In China, the YBB (pharmaceutical packaging standards) classifies glass containers into several types, among which <strong>mid\u2011borosilicate glass<\/strong> (Type I, neutral glass) and <strong>low\u2011borosilicate glass<\/strong> (Type II) are the most widely used for injectable products. Understanding their differences is critical for any drug manufacturer \u2013 from generic antibiotic producers to cutting\u2011edge vaccine and biologic developers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This guide provides a comprehensive, data\u2011driven comparison of the two materials. It draws on Chinese YBB requirements, USP &lt;660&gt;, EP 3.2.1, and ISO 8362\u20111 to help you make an informed selection. <strong>Zhengzhou PharGlass<\/strong>, a specialized supplier of advanced primary pharmaceutical packaging, offers high\u2011quality sterile glass vials, RTU rubber stoppers, and pre\u2011sterilized aluminum plastic caps. Our technical team regularly assists global clients in selecting the optimal glass type for their specific drug formulation and filling line.<\/p>\n\n\n\n<img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" class=\"gb-media-d9bc996d\" alt=\"\" title=\"3\" src=\"https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3.jpg\" srcset=\"https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3.jpg 1536w, https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3-300x200.jpg 300w, https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3-1024x683.jpg 1024w, https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3-768x512.jpg 768w, https:\/\/www.pharglass.com\/wp-content\/uploads\/2026\/06\/3-18x12.jpg 18w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">1. Core Composition Differences (Based on YBB Standards)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The YBB standards are the authoritative reference for pharmaceutical glass in China. The table below summarises the fundamental compositional differences between mid\u2011borosilicate (Type I) and low\u2011borosilicate (Type II) glass.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Mid\u2011Borosilicate (Type I, Neutral Glass)<\/th><th>Low\u2011Borosilicate (Type II)<\/th><\/tr><\/thead><tbody><tr><td><strong>B\u2082O\u2083 (Boron trioxide)<\/strong><\/td><td>8% \u2013 13%<\/td><td>5% \u2013 8%<\/td><\/tr><tr><td><strong>Alkali metal oxides (Na\u2082O + K\u2082O)<\/strong><\/td><td>Low (&lt;7%)<\/td><td>Higher (8% \u2013 11%)<\/td><\/tr><tr><td><strong>Coefficient of thermal expansion (CTE)<\/strong><\/td><td>3.3 \u00d7 10-\u2076 \/\u00b0C<\/td><td>4.5 \u2013 6.5 \u00d7 10\u207b\u2076 \/\u00b0C<\/td><\/tr><tr><td><strong>Hydrolytic resistance class<\/strong><\/td><td>Class 1 (highest)<\/td><td>Class 2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Key insight: The higher B\u2082O\u2083 content in mid\u2011borosilicate glass creates a stable silica network that immobilises alkali ions. Low\u2011borosilicate glass has a lower B\u2082O\u2083 content and more free alkalis, which compromises long\u2011term chemical durability, especially under aggressive conditions.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">2. Five Key Performance Differences<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">2.1 Chemical Stability \u2013 The Most Critical Distinction<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mid\u2011borosilicate (Type I)<\/strong><br>Due to its low alkali content and dense glass network, Type I glass is chemically inert. It resists attack by acids, alkalis, and water. Under autoclaving (121\u00b0C) or prolonged contact with drug solutions, it releases <strong>negligible sodium and other alkaline ions<\/strong>. This virtually eliminates the risk of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Glass delamination (thin glass flakes detaching into the drug product)<\/li>\n\n\n\n<li>Visible particles (\u201cwhite spots\u201d)<\/li>\n\n\n\n<li>pH drift<\/li>\n\n\n\n<li>Leachable\/extractable contamination<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The hydrolytic resistance test per USP &lt;660&gt; and EP 3.2.1 consistently places Type I glass in the highest Class 1 rating, making it suitable for all parenteral applications, including the most sensitive biologics and vaccines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Low\u2011borosilicate (Type II)<\/strong><br>The higher alkali content makes Type II glass inherently less stable. When storing acidic (pH &lt;5) or alkaline (pH &gt;9) solutions, or after repeated heat sterilisation, Type II glass can release alkali ions into the drug product, causing pH change. In long\u2011term storage (&gt;2 years), delamination and visible particle formation become real risks.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>However<\/strong>, for neutral drug solutions (pH 5\u20138) that are not subject to extreme temperature cycles, Type II glass performs adequately and complies with YBB and pharmacopoeial requirements for certain applications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2.2 Thermal Stability (Shock Resistance &amp; Breakage)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mid\u2011borosilicate (Type I)<\/strong><br>With a CTE of only 3.3 \u00d7 10\u207b\u2076 \/\u00b0C, Type I glass can withstand rapid temperature differences of <strong>150\u2013200\u00b0C<\/strong> without cracking. This makes it the only choice for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Lyophilisation (freeze\u2011drying), where vials go from \u201340\u00b0C freezing to +60\u00b0C warming<\/li>\n\n\n\n<li>Steam sterilisation (121\u00b0C) followed by immediate cooling<\/li>\n\n\n\n<li>Repeated thermal cycling<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In industrial lyophilisation lines, the breakage rate of high\u2011quality Type I vials (e.g., from Zhengzhou PharGlass) is <strong>&lt;0.3%<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Low\u2011borosilicate (Type II)<\/strong><br>The higher CTE (4.5\u20136.5 \u00d7 10\u207b\u2076 \/\u00b0C) limits the thermal shock resistance to about <strong>\u226470\u00b0C<\/strong> temperature difference. Therefore, Type II vials are <strong>not recommended for lyophilisation or rapid heating\/cooling cycles<\/strong>. Their breakage rate in freeze\u2011drying processes can reach <strong>2.7%<\/strong>, leading to significant production losses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Advantage<\/strong>: For standard boiling water sterilisation or ambient filling processes, Type II vials perform reliably and do not crack unexpectedly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2.3 Visual Appearance and Dimensional Precision<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mid\u2011borosilicate (Type I)<\/strong><br>The glass is highly transparent, free of the greenish tint often seen in lower\u2011grade glasses. The manufacturing process (precision tubing drawing) yields tight tolerances on wall thickness, outer diameter, and neck finish. Excellent batch\u2011to\u2011batch consistency ensures reliable sealing with rubber stoppers and reduces reject rates on high\u2011speed filling lines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Low\u2011borosilicate (Type II)<\/strong><br><strong>Advantage<\/strong>: Easier to melt and form, which historically made it attractive for domestic Chinese production.<br><strong>Disadvantage<\/strong>: Most Type II vials exhibit a slight greenish colour. Dimensional variations (wall thickness, roundness, neck concentricity) are larger than those of Type I. Within the same batch, some vials may be thicker on one side \u2013 a known cause of stopper leakage or machine jams.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2.4 Production Cost<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mid\u2011borosilicate (Type I)<\/strong><br>Higher raw material costs (boron compounds, high\u2011purity silica), more energy\u2011intensive melting, and precision tube\u2011drawing equipment make Type I vials significantly more expensive. Typical price range: <strong>2.5 to 5 times<\/strong> the cost of low\u2011borosilicate vials.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Low\u2011borosilicate (Type II)<\/strong><br><strong>Core advantage<\/strong>: Low material cost, abundant domestic production capacity in China, and mature manufacturing technology. For high\u2011volume, low\u2011margin products, the cost saving is substantial. Many local Chinese pharmaceutical plants still prefer Type II for conventional injections.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2.5 Mechanical Strength<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Type I glass has a more compact internal structure, offering slightly better resistance to impact, dropping, and scratching. Type II glass is more brittle and can chip or shed particles when mechanically stressed. However, for routine automated filling lines with proper handling, both types exhibit acceptable breakage rates \u2013 provided the filling line is calibrated for the specific vial dimensions.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">3. Pros and Cons Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u2705 Mid\u2011Borosilicate (Type I) Glass<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Advantages<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Excellent chemical inertness<\/strong> \u2013 suitable for strong acids, strong alkalis, sensitive biologics, vaccines, and any product requiring long shelf life (2\u20135 years) without pH shift or extractables.<\/li>\n\n\n\n<li><strong>Superior thermal stability<\/strong> \u2013 mandatory for freeze\u2011dried products, prefilled syringes, and cartridge systems.<\/li>\n\n\n\n<li><strong>Global pharmacopoeia compliance<\/strong> \u2013 meets USP, EP, JP, and ChP standards. Preferred or even required (e.g., China\u2019s consistency evaluation for generic injectables) for export drugs and high\u2011risk parenterals.<\/li>\n\n\n\n<li><strong>Low delamination risk<\/strong> \u2013 confirmed by USP delamination tests.<\/li>\n\n\n\n<li><strong>High dimensional uniformity<\/strong> \u2013 reduces stoppering failures and filling line stoppages.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Disadvantages<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>High procurement cost (2.5\u20135\u00d7 of Type II)<\/li>\n\n\n\n<li>Requires specialised manufacturing; limited number of qualified suppliers<\/li>\n\n\n\n<li>Higher inventory cost<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Typical applications<\/strong><br>Vaccines, biologics, monoclonal antibodies, gene therapies, lyophilised powders, injectables with extreme pH (&lt;4 or &gt;9), and any drug intended for global markets.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\u2705 Low\u2011Borosilicate (Type II) Glass<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Advantages<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Significantly lower cost<\/strong> \u2013 reduces primary packaging expense by a large margin.<\/li>\n\n\n\n<li><strong>Adequate for neutral formulations<\/strong> (pH 5\u20138) under conventional conditions; meets YBB and ChP requirements for many standard injections.<\/li>\n\n\n\n<li><strong>Abundant domestic Chinese supply<\/strong> \u2013 short lead times, flexible minimum order quantities, mature manufacturing base.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Disadvantages<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Unsuitable for strong acids, strong alkalis, or long\u2011term storage of sensitive molecules.<\/li>\n\n\n\n<li>Higher risk of delamination, visible particles, and pH drift when exposed to aggressive drugs or thermal stress.<\/li>\n\n\n\n<li>Not recommended for lyophilisation or extreme temperature changes.<\/li>\n\n\n\n<li>Slightly lower dimensional consistency.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Typical applications<\/strong><br>Conventional water\u2011based injections (e.g., vitamins, common antibiotics like penicillin, ceftriaxone), oral liquids, syrups, external tinctures, and solid\u2011dosage bottles (tablets, capsules) where glass is used as a secondary or non\u2011parenteral container.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">4. Selection Guide \u2013 A Simple Rule of Thumb<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>For export drugs, vaccines, lyophilised products, and formulations with extreme pH (acidic or alkaline) \u2192 Choose mid\u2011borosilicate (Type I).<\/strong><br><strong>For routine domestic antibiotics in neutral pH, oral liquids, or neutral conventional injections \u2192 Low\u2011borosilicate (Type II) may be acceptable, but always validate.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">When in doubt, conduct stability studies per ICH guidelines, including hydrolytic resistance and delamination tests, using your actual drug product.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">5. Why Zhengzhou PharGlass Recommends Type I for Most Modern Injectables<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Zhengzhou PharGlass<\/strong> specialises in <strong>advanced primary pharmaceutical packaging<\/strong>. Our sterile glass vials are manufactured from Type I borosilicate tubing, fully compliant with ISO 8362\u20111, YBB, USP &lt;660&gt;, and EP 3.2.1. We offer nests, tubs, and tray configurations pre\u2011sterilised and ready\u2011to\u2011use (RTU), designed to integrate seamlessly into your aseptic filling lines (isolators, RABS, or robotic fill\u2011finish platforms).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Although low\u2011borosilicate glass still has a place in low\u2011risk, neutral\u2011pH, cost\u2011sensitive products, the global trend \u2013 reinforced by regulatory bodies like FDA, EMA, and China\u2019s NMPA \u2013 is shifting toward Type I glass for all injectables, especially those requiring long shelf life or those classified as high\u2011risk. The 2023 revision of GMP Annex 1 emphasises container closure integrity (CCI) and extractables\/leachables risk assessment, where Type I glass offers inherent advantages.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For manufacturers seeking to future\u2011proof their packaging systems and meet stringent international standards, <strong>Zhengzhou PharGlass<\/strong> provides validated Type I glass vials that eliminate the trade\u2011off between drug safety and line efficiency.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">6. Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The choice between mid\u2011borosilicate and low\u2011borosilicate glass vials is not simply about cost \u2013 it is about <strong>drug stability, patient safety, and regulatory compliance<\/strong>. Type I glass offers superior chemical and thermal performance, making it the preferred material for advanced therapies and export markets. Type II glass remains a cost\u2011effective option for stable, neutral formulations used in well\u2011controlled domestic environments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As a responsible packaging partner, <strong>Zhengzhou PharGlass<\/strong> encourages manufacturers to conduct product\u2011specific compatibility studies. Our technical team is available to provide data, samples, and integration support for both glass types, though our core offering is the higher\u2011performance Type I range \u2013 because the industry\u2019s future is moving towards higher quality, lower risk, and global harmonisation.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>This article references the Chinese YBB standards, USP &lt;660&gt;, EP 3.2.1, ISO 8362\u20111, and current industry data on thermal shock resistance and delamination. For specific validations, always consult your internal quality unit and regulatory requirements.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Introduction Pharmaceutical glass vials are the backbone of parenteral drug containment. Their material composition directly affects drug stability, container closure integrity, and patient safety. In &#8230; <a title=\"Mid\u2011Borosilicate vs. Low\u2011Borosilicate Glass Vials for Pharmaceutical Packaging: Composition, Key Differences, Pros, and Cons\" class=\"read-more\" href=\"https:\/\/www.pharglass.com\/de\/mid-borosilicate-vs-low-borosilicate-glass-vials-for-pharmaceutical-packaging-composition-key-differences-pros-and-cons\/\" aria-label=\"Mehr Informationen \u00fcber Mid\u2011Borosilicate vs. Low\u2011Borosilicate Glass Vials for Pharmaceutical Packaging: Composition, Key Differences, Pros, and Cons\">Weiterlesen &#8230;<\/a><\/p>","protected":false},"author":1,"featured_media":1913,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-2245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry-standards","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50"],"_links":{"self":[{"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/posts\/2245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/comments?post=2245"}],"version-history":[{"count":2,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/posts\/2245\/revisions"}],"predecessor-version":[{"id":2255,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/posts\/2245\/revisions\/2255"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/media\/1913"}],"wp:attachment":[{"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/media?parent=2245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/categories?post=2245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharglass.com\/de\/wp-json\/wp\/v2\/tags?post=2245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}